Alogliptin alleviates type 2 diabetes burden

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1643, 2008-01, pp. : 11-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Alogliptin benzoate for the treatment of type 2 diabetes

By Rendell Marc   Drincic Andjela   Andukuri Radha  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 4, 2012-03 ,pp. : 553-563

Informa Healthcare

Access to resources Recommend Favorite

Alogliptin benzoate for the treatment of type 2 diabetes

By Seino Yutaka   Yabe Daisuke  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 6, 2014-04 ,pp. : 851-863

Informa Healthcare

Access to resources Recommend Favorite

Alogliptin: A Review of its Use in the Management of Type 2 Diabetes Mellitus

By Scott Lesley J.  

Drugs, Vol. 70, Iss. 15, 2010-10 ,pp. : 2051-2072

Adis International

Access to resources Recommend Favorite

Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

By Pratley Richard E  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 3, 2009-02 ,pp. : 503-512

Informa Healthcare

Access to resources Recommend Favorite

New Insights into the Combined Burden of Type 2 Diabetes and Hypertension

By  

Heart Drug, Vol. 3, Iss. 1, 2003-07 ,pp. : 25-33

Karger

Access to resources Recommend Favorite